Departments of Pharmacology and Anesthesiology, School of
Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas
(H.R.A., E.A.M., M.P.B.); and Department of Neurology, Washington
University School of Medicine, St. Louis, Missouri (M.J.G.)
Barbiturate-induced anesthesia is a complex mechanism that probably
involves several ligand-gated ion channel superfamilies. One of these
superfamilies includes the archetypical nicotinic acetylcholine
receptor (nAChR), in which barbiturates act as noncompetitive antagonists. In this regard, we used the Torpedo
californica nAChR and a series of barbiturate analogs to
characterize the barbiturate binding site(s) on this superfamily
member. [14C]Amobarbital binds to one high-affinity
(Kd = 3.7 µM) and several (~11)
low-affinity (Kd = 930 µM) sites on
the resting and desensitized nAChRs, respectively. Characteristics of
the barbiturate binding site on the resting nAChR include: (1) a tight
structure-activity relationship. For example, the barbiturate
isobarbital [5-ethyl-5'-(2-methylbutyl) barbituric acid] is >10-fold
less potent than its formula isomer amobarbital
[5-ethyl-5'-(3-methylbutyl) barbituric acid] in inhibiting [14C]amobarbital binding. (2) A binding locus within the
pore of the nAChR ion channel. Each of the barbiturate analogs
inhibited the binding of [3H]tetracaine or
photoincorporation of
3-trifluoromethyl-3-(m-[125I]iodophenyl)
diazirine in a mutually exclusive manner. (3) Stereoselective binding.
The R(+)-enantiomers of isobarbital and pentobarbital are ~2-fold more potent in inhibiting
3-trifluoromethyl-3-(m-[125I]iodophenyl)
diazirine photoincorporation than the S(
)-enantiomers. Finally, molecular modeling suggests that within the channel, the
pyrimidine ring of the barbiturate is located just above the highly
conserved leucine ring (M2-9; e.g.,
Leu-265), whereas the 5' side
chain projects downward, and depending upon its conformation, introduces steric hindrance to binding because of the restriction in
the lumen of the channel introduced by the leucine side chains.
 |
Introduction |
Barbiturates,
as a class of compounds, exert a broad range of pharmacological
actions, including sedation, general anesthesia, and anticonvulsant and
anxiolytic effects. Many of these actions are exerted by inhibiting or
enhancing the action of several ligand-gated ion channel (LGIC)
receptors (reviewed in Franks and Lieb, 1994
; Krasowski and Harrison,
1999
). One of the LGIC superfamilies that may play a role in the
pharmacological actions of barbiturates includes both muscle- and
neuronal-type nicotinic acetylcholine (nAChR) and type 3 5-hydroxytryptamine (5-HT3R) excitatory
receptors, as well as type A (GABAAR) and type C
-aminobutyric acid and glycine inhibitory receptors (Galzi and
Changeux, 1994
; Arias, 2000
). For example, there have been recent
reports of anesthetic supersensitivity for neuronal nAChRs (Evers and
Steinbach, 1997
), although the role of neuronal nAChRs in
barbiturate-induced anesthesia is considered questionable (Downie et
al., 2000
). Although a wealth of pharmacological data has accumulated
with respect to the interaction of barbiturates with the
GABAAR, a barbiturate binding site(s) has yet to
be identified (Serafini et al., 2000
). Based on the attractive
hypothesis by Eger et al. (1997)
, who states that general anesthetics
may produce immobility and amnesia by interacting with two different
target sites, barbiturate molecules might bind different ion channel
receptors (e.g., GABAAR and neuronal nAChRs), where each specific interaction would result in a particular
pharmacological action.
The low density of GABAARs in neural tissue as
well as the complexity of interactions in dealing with an allosteric
protein, has made it difficult to directly identify a barbiturate
binding site on the GABAAR protein. Fortunately,
the Torpedo californica muscle-type nAChR provides a model
system for examining the interaction of barbiturates with this LGIC
superfamily. From Torpedo electroplaque tissue, postsynaptic
membranes that contain nAChRs at high specific activity (~50% of
total membrane protein) can be easily obtained and therefore the
receptor is amenable to many different methodological approaches,
including direct radioligand binding studies. Furthermore, the nAChR
and GABAAR not only exhibit amino acid sequence
homology but also, and perhaps more importantly, it is becoming
increasingly evident that these two receptors (and each of the LGIC
members) share considerable structural homology (Galzi and Changeux,
1994
). Barbiturates act as noncompetitive antagonists (NCA) of nAChR function and previous studies have demonstrated the presence of a
stereoselective, functional binding site on the receptor (reviewed in
Tonner and Miller, 1995
; Dilger et al., 1997
). The nAChR exists in at
least three interconvertible conformations: a resting (closed) state;
an open channel state; and a nonconducting desensitized state
(Corringer et al., 1999
). It is evident that barbiturate interaction is
highly dependent on the conformational state of the receptor (de
Armendi et al., 1993
).
In this study, we wished to more fully characterize the interaction of
barbiturates with the resting and desensitized states of the nAChR by
identifying important structure-activity relationships for barbiturate
binding in each receptor conformation and by identifying a specific
binding site(s). First, we examined the equilibrium binding of
[14C]amobarbital to the Torpedo
nAChR in each conformation and then tested the ability of different
barbiturates and formula isomers of a given barbiturate to displace
[14C]amobarbital binding to the receptor. Next,
we identified the barbiturate-binding site on the resting and
desensitized nAChR by characterizing barbiturate interaction with
well-characterized NCAs. For the resting state of the nAChR, the NCAs
[3H]tetracaine and
3-trifluoromethyl-3-(m-[125I]iodophenyl)
diazirine ([125I]TID) were used. These ligands
bind to a single high-affinity site on the resting nAChR. Based on the
binding and photoincorporation properties, a binding site in the pore
of the ion channel in the resting state has been determined for each
NCA (White et al., 1991
; White and Cohen, 1992
; Gallagher and Cohen,
1999
; Middleton et al., 1999
). For the desensitized state, the NCAs
[piperidyl-3,4-3H
(N)]-(N-(1-(2-thienyl)cyclohexyl)-3,4-piperidine
([3H]TCP) and quinacrine were used. TCP is the
structural analog of phencyclidine (PCP), which binds to a single
high-affinity site in the desensitized channel believed to be located
near the serine ring (position 6) of the M2 transmembrane domain
(reviewed in Arias, 1998
). Newer data indicate that PCP effectively
binds to residues in the open channel at position 6, 8, and 10 (e.g., M2-6, M2-8, and M2-10) (Eaton et al., 2000
). The fluorescent NCA quinacrine also binds to a single high-affinity site on the
desensitized nAChR, but at a nonluminal binding site believed to be
located at the nonannular lipid domain of the receptor (Arias, 1997
;
reviewed in Arias, 1998
). Finally, the stereoselectivity of barbiturate binding was examined and a molecular model of the binding site in the
resting nAChR channel constructed.
 |
Experimental Procedures |
Materials.
[3H]TCP (57.6 Ci/mmol)
was obtained from New England Nuclear Research Products (Boston, MA),
[125I]TID (~10 Ci/mmol) from Amersham
Pharmacia Biotech (Piscataway, NJ) and both were stored in ethanol at
20°C and 4°C, respectively. [3H]Tetracaine (36 Ci/mmol) was a gift from Dr.
Jonathan Cohen (Harvard Medical School, Boston, MA),
[14C]amobarbital (50 Ci/mmol) was synthesized
by American Radiolabeled Chemicals (St. Louis, MO) and both were stored
in ethanol at
20°C. Amylbarbital [5-ethyl-5'-amyl barbituric
acid] and isobarbital [5-ethyl-5'-(2-methylbutyl) barbituric acid]
were synthesized by Gateway Chemical Technology (St. Louis, MO).
Quinacrine dihydrochloride, suberyldicholine dichloride,
carbamylcholine chloride (CCh), proadifen, amobarbital hydrochloride,
pentobarbital hydrochloride, tetracaine, and PCP were purchased from
Sigma Chemical Co. (St. Louis, MO). [1-(Dimethylamino)
napthalene-5-sulfonamido] ethyltrimethylammonium perchlorate
(dansyltrimethylamine) was obtained from Pierce Chemical Co. (Rockford,
IL). Other organic chemicals were of the highest purity available.
Preparation of nAChR-Rich Membranes.
nAChR-rich membranes
were prepared from frozen T. californica electric organs
obtained from Aquatic Research Consultants (San Pedro, CA) by
differential and sucrose density gradient centrifugation, as described
previously (Pedersen et al., 1986
). The specific activities of these
membrane preparations were determined by the decrease in
dansyltrimethylamine (6.6 µM) fluorescence produced by the titration
of suberyldicholine into receptor suspensions (0.3 mg/ml) in the
presence of 100 µM PCP and ranged between 1.1 and 1.2 nmol of
suberyldicholine binding sites/mg of total protein (0.55-0.60 nmol
nAChR/mg protein). Dansyltrimethylamine excitation and emission
wavelengths were 280 and 546 nm, respectively. To reduce stray-light
effects a 530-nm cutoff filter was placed in the path of the
dansyltrimethylamine emission beam. The nAChR membrane preparations (in
~36% sucrose, 0.02% NaN3) were stored at
80°C.
Purification of Barbiturate Enantiomers.
The
R(+)- and S(
)- enantiomers of pentobarbital and
isobarbital were purified by chiral HPLC using a Nucleodex
permethylated
-cyclodextrin column (200 × 4 mm; Machery-Nagel,
Easton, PA). The solvent methanol/water/triethylammonium acetate, pH
4.0 (adjusted with acetic acid), was used as the mobile phase in the
proportion 65:35:0.1 or 45:55:0.1 (v/v/v) for separation of
pentobarbital or isobarbital enantiomers, respectively (Tomlin et al.,
1999
). An isocratic elution gradient was employed (0.2 ml/min) and the elution of each enantiomer was monitored by absorbance at 240 nm. The
final concentration and purity (>90%) of each enantiomer was
determined using HPLC peak heights and a standard concentration curve.
Equilibrium Binding of [14C]Amobarbital to nAChR
Membranes.
The binding of [14C]amobarbital
to native nAChR-rich membranes was determined by a centrifugation assay
similar to that described for [3H]dizocilpine
binding (Arias et al., 2001
). Briefly, nAChR membranes (0.3 µM nAChR)
were suspended in vesicle dialysis buffer (VDB, 10 mM MOPS, 100 mM
NaCl, 0.1 mM EDTA, and 0.02% NaN3, pH 7.5) with
increasing concentrations of [14C]amobarbital
in the absence (resting state) or in the presence of 1 mM CCh
(desensitized state), at a final volume of 150 µl. [14C]Amobarbital/amobarbital concentration
ratios of approximately 0.53 and 0.027 were used in the experiments
with nAChRs in the resting and in the desensitized states,
respectively; thus, the actual amobarbital concentration was the sum of
[14C]amobarbital + unlabeled amobarbital. The
final concentration of amobarbital ranged between 0.3 and 13 µM and
between 20 and 800 µM, for experiments with nAChRs in the resting or
desensitized state, respectively. To determine nonspecific
[14C]amobarbital binding, a parallel set of
tubes was prepared containing 60 µM tetracaine (resting state
experiments) or 100 µM PCP (desensitized state experiments). We used
these drug concentrations to obtain nonspecific binding because
tetracaine binds with high affinity [dissociation constant
(Kd) = 0.5 µM; Middleton et al.,
1999
] to the nAChR in the resting state and PCP binds with high
affinity (Kd = 0.46 µM; Arias, 1999
) to
the desensitized nAChR. The membrane suspensions were equilibrated for
1 h at room temperature. Bound ([B]) amobarbital was then
separated from the free ([F]) ligand by centrifugation at 18,000 rpm
for 1 h using a JA-20 rotor in a Beckman J2-HS centrifuge (Beckman
Coulter, Inc., Fullerton, CA). After centrifugation, 50-µl aliquots
of the supernatant were removed and assayed for total radioactivity in
3 ml of Bio-Safe II (Research Products International Corp., Mount
Prospect, IL) using a Packard 1900 TR scintillation counter (Packard,
Meriden, CT). The remainder of the supernatant was aspirated, the tubes inverted, allowed to drain for 30 min, and then any residual liquid was
removed with a cotton swab. The pellets were resuspended in 100 µl of
10% SDS, transferred to scintillation vials with 3 ml of Bio-Safe II,
and the radioactivity (14C dpm) was determined.
Using the graphics program Prism (GraphPad Software, San Diego, CA),
binding data were fit to the Rosenthal-Scatchard plot (Scatchard, 1949
)
using the equation:
|
(1)
|
where Bmax, the number of
amobarbital binding sites, can be estimated from the x-intersect (when
y = 0) of the plot [B]/[F] versus [B]. The number of
amobarbital binding sites per receptor is then calculated from the
concentration of nAChRs (0.3 µM) and the values are reported in Table
1. The Kd
value of amobarbital is obtained from the negative reciprocal of the
slope (Table 1).
View this table:
[in this window]
[in a new window]
|
TABLE 1
Dissociation constant (Kd) and stoichiometry of
amobarbital binding to nAChRs in the desensitized and resting state.
The Kd values in the nAChR resting state were
obtained from the negative reciprocal of the slope of Fig. 1B,
according to eq. 1. The values in the desensitized state were estimated
from Fig. 1C. The number of amobarbital binding sites per nAChR in the
resting state was obtained from the x-intersect of Fig. 1B,
according to eq. 1, and considering the concentration of receptor
employed (0.3 µM). The stoichiometry in the desensitized state was
estimated from Fig. 1C. Values are reported as mean ± S.D.
r2 expresses goodness of the fit.
|
|
Barbiturate-Induced Inhibition of [3H]Tetracaine,
[14C]Amobarbital, and [3H]TCP Binding and
[125I]TID Photoincorporation.
To determine the
effect of barbiturates on the specific binding of
[3H]tetracaine,
[14C]amobarbital,
[3H]TCP, or on
[125I]TID photoincorporation into the nAChR,
0.2 µM nAChR native membranes were suspended in 8 ml of VDB buffer
with either ~11 nM [3H]tetracaine, 7.5 µM
[14C]amobarbital, or ~430 nM
[125I]TID in the absence of CCh (resting
state), or with ~6.5 nM [3H]TCP in the
presence of 0.4 mM CCh (desensitized state). The total volume was then
divided into aliquots, and increasing concentrations of a given
barbiturate or barbiturate enantiomer were added from ethanolic stock
solutions (ethanol concentration <1%) to each tube and the membrane
suspension allowed to incubate for 2.5 h at room temperature. For
[125I]TID photolabeling experiments, membranes
were then irradiated for 7 min at a distance of <1 cm with a 365-nm
lamp (Spectroline model EN-280L; Spectronics, Westbury, NY) and labeled
polypeptides separated by SDS-polyacrylamide gel (Blanton et al.,
2000
). For competition binding experiments, after centrifugation
(18,000 rpm for 1 h) of the samples, the
3H- or 14C-containing
pellets were resuspended in 100 µl of 10% SDS and transferred to a
scintillation vial with 5 ml of Bio-Safe II. The bound fraction was
determined by scintillation counting, with nonspecific binding
determined in the presence of 200 µM amobarbital (resting state
experiments) or 200 µM proadifen (desensitized state experiments).
For [125I]TID photolabeling experiments, the
polyacrylamide gel bands containing the nAChR
-subunit were excised
and the amount of 125I was measured (cpm) with a
Packard Cobra II gamma counter. Nonspecific [125I]TID photoincorporation into the
-subunit was determined in the presence of 0.4 mM CCh as described
in Blanton et al. (2000)
.
The concentration-response data were curve-fit by nonlinear
least-squares analysis (one-site competition) using the program Prism
and the corresponding IC50 values were
calculated. Taking into account that the nAChR presents a single
high-affinity binding site either for tetracaine (Middleton et al.,
1999
), TID (White et al., 1991
), TCP (Katz et al., 1997
, and references
therein), or for amobarbital (this article), the observed
IC50 values were transformed into
Ki values using the Cheng-Prusoff
relationship (Cheng and Prusoff, 1973
):
|
(2)
|
where [NCA] is the initial concentration of the labeled
noncompetitive antagonist ([3H]tetracaine,
[3H]TCP,
[14C]amobarbital, or
[125I]TID) and
KdNCA is the
dissociation constant for tetracaine (0.5 µM; Middleton et al.,
1999
), TCP (~0.2 µM; Katz et al., 1997
), TID (4 µM; White et al.,
1991
), or amobarbital (3.7 µM; see Table 1), respectively.
Effect of Pentobarbital on Quinacrine Binding to the Desensitized
nAChR.
To determine whether barbiturates interact competitively
with the quinacrine binding site on the desensitized nAChR, which is
located at the nonannular lipid domain of the nAChR (Arias, 1997
;
reviewed in Arias, 1998
), the effect of pentobarbital on the apparent
Kd of quinacrine was measured as described
previously (Arias, 1997
; Arias et al., 2001
). Briefly, direct
titrations of quinacrine into nAChR suspensions (0.3 µM) in VDB, CCh
(1 mM), in the absence or in the presence of proadifen (200 µM), and
different concentrations of pentobarbital to determine the apparent
Kd values were assessed in an
SLM-Aminco-Bowman Series 2 Luminiscence Spectrometer using 0.5 × 0.5-cm quartz cuvettes. Proadifen was added to define the specific or
proadifen-sensitive fluorescence associated with the binding of
quinacrine to its high-affinity site on the desensitized nAChR. The
nAChR native membrane suspensions containing pentobarbital were allowed
to incubate for at least 3 h and up to 5 h at room temperature before the beginning of the titration. A stock solution of
16 mM pentobarbital was prepared in VDB. Quinacrine excitation and
emission wavelengths were 450 and 502 nm, respectively. To reduce
stray-light effects, a 450-nm narrow band and a 495-nm cutoff filter
was placed in the path of excitation and emission beams, respectively.
Estimates of the apparent Kd values of
quinacrine were made by fitting the plots of the specific
(proadifen-sensitive) changes in quinacrine fluorescence versus added
ligand concentration to a four-parameter logistic equation (sigmoid).
To determine the apparent inhibition constant
(Ki) of pentobarbital from the quinacrine
displacement experiments, a Schild-type plot was used according to the
following equation (Schild, 1949
):
|
(3)
|
where Kd and
Kdpentobarbital are
the apparent dissociation constants of quinacrine in the absence or
presence, respectively, of a certain concentration of pentobarbital and
pA2 is the negative logarithm of the
concentration of pentobarbital that reduces the apparent affinity of
quinacrine by a factor of 2. In other words, when Kdpentobarbital = 2Kd, then
log[(Kdpentobarbital/Kd)
1] = 0, and log(pA2) = log
Ki. In this regard, the
Ki value can be graphically calculated as
the antilog of the x-intersect (when y = 0) from the
log[(Kdpentobarbital/Kd)
1] versus log[pentobarbital] plot. To determine whether the
observed displacement was elicited by a steric or an allosteric mechanism, the slope of the Schild plot was considered.
 |
Results |
Equilibrium Binding of [14C]Amobarbital to nAChR-Rich
Membranes.
Initial studies were done to confirm the results of
Dodson et al. (1987)
that demonstrated the presence of saturable
high-affinity binding site for amobarbital on the resting T. californica nAChR. Secondly, we wished to characterize the binding
of amobarbital to the desensitized nAChR.
Resting State.
In the absence of agonist (i.e., the resting
state), [14C]amobarbital binding to nAChR
membranes (7.5 µM [14C]amobarbital, 0.3 µM
nAChR) was reduced 38% by the addition of an excess (125 µM) of
unlabeled amobarbital (446 versus 273 pmol/mg protein). Addition of an
excess of the NCA tetracaine (60 µM) reduced the binding of
[14C]amobarbital to the receptor to a level
equivalent to that observed with an excess of amobarbital, whereas
addition of the competitive antagonist
-bungarotoxin (10 µM) had
very little effect on the total binding (410 pmol/mg). These results
are similar to those reported by Dodson et al. (1987)
; therefore, we
proceeded to more fully characterize the binding of
[14C]amobarbital to the resting nAChR, using an
excess (60 µM) of tetracaine to define the level of displaceable
(specific) binding. Figure 1A shows the
total, nonspecific, and specific
[14C]amobarbital binding to nAChR native
membranes. Figure 1B shows the Rosenthal-Scatchard plot for this
specific binding. These experimental results indicate the existence of
a single (0.89 ± 0.14 binding sites/nAChR) high-affinity
(Kd = 3.7 ± 0.7 µM) amobarbital
binding site on the T. californica muscle-type nAChR when it is in the resting state (Table 1).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 1.
[14C]Amobarbital binding to nAChR-rich
membranes in the resting and desensitized state. A, total ( ),
nonspecific ( ), and specific ( ) [14C]amobarbital
binding in the resting state. nAChR-rich membranes (0.3 µM) were
equilibrated (1 h) with increasing concentrations of
[14C]amobarbital (0.3-13 µM) in the absence of CCh.
nAChR membranes were then centrifuged and the amount of 14C
cpm contained in the pellets was measured as described under
Experimental Procedures. Nonspecific binding was
determined in the presence of tetracaine (60 µM). Specific or
tetracaine-sensitive [14C]amobarbital binding is defined
as total minus nonspecific [14C]amobarbital binding. B,
Rosenthal-Scatchard plots for [14C]amobarbital specific
binding in the resting state. C, Rosenthal-Scatchard plots for
[14C]amobarbital specific binding in the desensitized
state (i.e., in the presence of 1 mM CCh). In this case, the specific
binding is defined as total (determined in the concentration range of
20 to 800 µM [14C]amobarbital, data not shown) minus
the nonspecific [14C]amobarbital binding (determined in
the presence of 100 µM PCP). The Kd values
in the resting and desensitized states were determined from the
negative reciprocal of the slope of three separate experiments
according to eq. 1, then averaged, and finally summarized in Table 1.
These plots are the result of three different experiments with
calculated values reported ± S.D.
|
|
Desensitized State.
To assess
[14C]amobarbital binding to the desensitized
nAChR (in the presence of 1 mM CCh), higher concentrations of
[14C]amobarbital were used and the addition of
100 µM unlabeled PCP was used to determine nonspecific binding (Fig.
1C). The Kd and the stoichiometry were
difficult to calculate accurately because of the low level of specific
binding. However, we estimate that the nAChR in the desensitized state
bears approximately 11 low-affinity (Kd = 940 ± 380 µM) amobarbital binding sites (Table 1).
Inhibition of [14C]Amobarbital Binding to the Resting
nAChR with Barbiturate Analogs.
The effect of barbiturates on
displaceable [14C]amobarbital binding to the
resting nAChR was examined by centrifugation assay. As expected,
amobarbital (Fig. 2) displaced
[14C]amobarbital binding in a
concentration-dependent fashion (Fig. 3)
with a Ki value of 4 µM (Table
2), which is nearly identical to the
determined Kd (3.7 µM, Table 1).
Pentobarbital also displaced [14C]amobarbital
binding in a concentration-dependent fashion, but with a
Ki value (38 µM) that is 10-fold higher
than that of amobarbital. This result is somewhat surprising given that
pentobarbital and amobarbital have identical empirical formulas, being
formula isomers (Fig. 2) that differ in the point of branching on the
5' side chain [5'(1-methylbutyl) versus 5'(3-methylbutyl),
respectively]. Furthermore, the two barbiturates have nearly identical
octanol/water partition coefficients and therefore physicochemical
differences such as hydrophobicity are not likely the source of
differences in binding affinity. Noting this surprising difference in
potency, Dodson et al. (1990)
suggested that the simplest explanation
was steric hindrance for binding to the barbiturate site on the resting nAChR. To explore this further, we synthesized and tested two additional formula isomers: isobarbital [5'(2-methylbutyl)] and amylbarbital (5'-amyl) (see chemical structures in Fig. 2).
Amylbarbital, in which the 5' side chain has no branching, displaced
[14C]amobarbital binding with a potency
(Ki = 2.6 µM) that was even slightly
greater that that of amobarbital (Fig. 3). In contrast, isobarbital had
a potency (Ki = 54 µM) that was slightly
less than that of pentobarbital. Remarkably, by moving the point of branching by a single carbon atom (isobarbital to amobarbital) the
result is a 10-fold shift in potency (i.e., binding affinity).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 2.
Chemical structures of barbiturate analogs. The
chemical structure of amobarbital, amylbarbital, pentobarbital, and
isobarbital are shown. The asterisks (*) indicate the position of the
chiral carbon on both pentobarbital and isobarbital.
|
|

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 3.
Barbiturate-induced displacement of
[14C]amobarbital binding to nAChRs in the resting state.
nAChR-rich membranes (0.2 µM) were equilibrated (1 h) with
[14C]amobarbital (7.5 µM), in the presence of
increasing concentrations (0.01-200 µM) of amobarbital ( ),
amylbarbital ( ), pentobarbital ( ), and isobarbital ( ). The
nAChR membranes were then centrifuged and the radioactivity present in
the pellets measured as described under Experimental
Procedures. Nonspecific binding was determined in the presence
of 200 µM amobarbital. Each plot is the average of two different
experiments. The IC50 value for each barbiturate was
calculated by nonlinear least-squares fit for a single binding site.
Ki values for each barbiturate were
calculated using these IC50 values according to eq. 2 and
summarized in Table 2.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 2
Inhibition constant (Ki) for select barbiturates and
R(+)- or S( )-enantiomers determined for
inhibition of either binding or photolabeling of NCAs to their
respective sites on nAChRs in the resting conformational state
The Ki values (averaged) were calculated using the
Cheng-Prusoff relationship (eq. 2) and the IC50 values obtained
from Figs. 3 ([14C]amobarbital), 4A and 5 ([125I]TID), and 4B ([3H]tetracaine).
|
|
Barbiturate-Induced Inhibition of [125I]TID and
[3H]Tetracaine Binding to the Resting nAChR.
To more
fully examine the molecular determinants of the barbiturate-binding
site in the resting nAChR, we characterized the interaction of
barbiturates with two NCAs (tetracaine and TID). Each of these NCAs has
well-characterized binding properties and for each, a binding locus
within the resting nAChR channel has been established (White et al.,
1991
; White and Cohen, 1992
; reviewed in Arias, 1998
; Gallagher and
Cohen, 1999
; Middleton et al., 1999
). In the absence of agonist,
greater than 95% of the [125I]TID
photoincorporation into the nAChR
-subunit reflects labeling of
specific residues in the channel-lining M2 segment and can be inhibited
by TID (as well as tetracaine) or by addition of agonist (White and
Cohen, 1992
; Blanton et al., 2000
). Each of the barbiturate analogs
(e.g., amobarbital, amylbarbital, pentobarbital, and isobarbital)
inhibited [125I]TID photoincorporation into the
-subunit (Fig. 4A) in a
concentration-dependent fashion and with potencies and rank order that
exactly paralleled inhibition of
[14C]amobarbital binding (Table 2). For
example, at 120 µM amobarbital, more than 93% of the specific
[125I]TID photoincorporation into the
-subunit is inhibited and the interaction seems to be formally
competitive (Ki = 6.9 µM;
nH = 0.96, r2 = 0.980).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 4.
Barbiturate-induced inhibition of
[125I]TID photoincorporation and
[3H]tetracaine binding to nAChRs in the resting state.
nAChR-rich membranes (0.2 µM) were equilibrated (1 h) with (A)
[125I]TID (~430 nM) or (B) [3H]tetracaine
(~11 nM), in the presence of increasing concentrations (0.01-200
µM) of either amobarbital ( ), amylbarbital ( ), pentobarbital
( ), or isobarbital ( ). For [125I]TID photolabeling
experiments (A), the membrane suspensions were irradiated with 365-nm
ultraviolet light for 7 min, the nAChR subunits separated by
SDS-polyacrylamide gel electrophoresis, and the 125I cpm in
the nAChR -subunit measured by gamma counting as described under
Experimental Procedures. Nonspecific photoincorporation
into the -subunit was determined in the presence of 400 µM CCh.
For [3H]tetracaine competition binding experiments (B),
nAChR membranes were centrifuged and the radioactivity present in the
pellets was measured as described under Experimental
Procedures. Nonspecific binding was determined in the presence
of 200 µM amobarbital. Each plot is the average of two different
experiments. IC50 values for each barbiturate were
calculated by nonlinear least-squares fit for a single binding site.
Ki values for each barbiturate were
calculated using these IC50 values according to eq. 2 and
summarized in Table 2.
|
|
The binding sites for TID and tetracaine in the resting nAChR channel
overlap; therefore, it was not surprising that nearly identical results
were observed for barbiturate inhibition of [3H]tetracaine binding to the nAChR (Fig. 4B,
Table 2). Again, as an example, 120 µM amylbarbital inhibited >97%
of the specific [3H]tetracaine binding to the
resting nAChR, and the inhibition seems to be formally competitive
(Ki = 6.3 µM;
nH = 0.91, r2 = 0.993). In reciprocal fashion,
tetracaine completely displaces specific
[14C]amobarbital binding to the resting nAChR
(data not shown). This inhibition seems to be formally competitive
(nH = 0.97, r2 = 0.997); and the
Ki value (~0.3 µM) is nearly identical
to the reported Kd for tetracaine (0.5 µM; Middleton et al., 1999
). For inhibition of
[14C]amobarbital,
[3H]tetracaine binding, or
[125I]TID photoincorporation, the same rank
order of potency was observed: amylbarbital > amobarbital
pentobarbital > isobarbital. Finally, with respect to inhibition
of [125I]TID photoincorporation into the
resting nAChR, additional barbiturates were examined (data not shown)
and are listed in order of rank potency: secobarbital
(IC50 = 123 µM), phenobarbital (366 µM), butabarbital (516 µM), barbital (1800 µM), and hexobarbital (5000 µM). These values are very similar to those reported for inhibition of [14C]amobarbital binding to the resting
nAChR (de Armendi et al., 1993
).
Stereoselectivity of Barbiturate Inhibition of
[125I]TID Photoincorporation into the Resting nAChR.
To obtain additional information about the molecular determinants of
the barbiturate-binding site in the resting nAChR channel, we next
examined the stereoselectivity of barbiturate binding. The
R(+)- and S(
)-enantiomers of pentobarbital and
isobarbital were purified by chiral HPLC from a racemic mix of both
optical isomers (data not shown). Each enantiomer was then used to
displace [125I]TID photoincorporation into the
-subunit of the resting nAChR (Fig.
5). From these experiments, we found that
for both pentobarbital and isobarbital the R(+)-enantiomer
is about 1.8-fold more potent in inhibiting
[125I]TID photoincorporation into the
-subunit than the S(
)-enantiomer (see Table 2). For
inhibition of [14C]pentobarbital binding to the
resting nAChR, Roth et al. (1989)
also found that the
R(+)-enantiomer of pentobarbital was more potent than the
S(
)-enantiomer in displacing binding, albeit with slightly
greater differences in potency (4-fold; 130 versus 525 µM,
respectively).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 5.
Barbiturate enantiomer-induced inhibition of
[125I]TID photoincorporation into nAChRs in the resting
state. nAChR-rich membranes (0.2 µM) were equilibrated (1 h) with
[125I]TID (~430 nM), in the presence of increasing
concentrations (0.01-200 µM) of barbiturate enantiomers:
R(+)-pentobarbital ( ) and
S( )-pentobarbital ( ) (A) and
R(+)-isobarbital ( ) and
S( )-isobarbital ( ) (B). Membrane suspensions were
irradiated with 365-nm ultraviolet light for 7 min, the nAChR subunits
separated by SDS-polyacrylamide gel electrophoresis, and the
125I cpm in the -subunit measured by gamma counting as
described under Experimental Procedures. Nonspecific
photoincorporation into the -subunit was determined in the presence
of 400 µM CCh. Each plot is the average of two different experiments.
IC50 values for each barbiturate were calculated by
nonlinear least-squares fit for a single binding site.
Ki values for each barbiturate were
calculated using these IC50 values according to eq. 2 and
summarized in Table 2.
|
|
Barbiturate-Induced Inhibition of [3H]TCP Binding to
the Desensitized nAChR.
To begin to characterize the low-affinity
barbiturate binding site(s) on the desensitized nAChR, we first
examined the effect of the same barbiturate analogs on
[3H]TCP binding (Fig.
6). TCP, which binds with high affinity
to the ion channel in the desensitized state (Katz et al., 1997
) is an
analog of the dissociative anesthetic and NCA PCP (reviewed in Arias,
1998
). Each barbiturate displaced specific
[3H]TCP binding to the desensitized nAChR in a
concentration-dependent fashion, albeit with substantially reduced
potencies relative to those observed for the resting nAChR (Fig. 6A).
As an example, 3 mM isobarbital inhibited >80% of the specific
[3H]TCP binding to the desensitized receptor
and the inhibition seemed to be formally competitive
(Ki = 582 µM
nH = 0.94;
r2 = 0.992). For inhibition of
[3H]TCP binding to the desensitized nAChR, the
barbiturate potencies follow the order: secobarbital
(Ki = 136 µM; data not shown) > pentobarbital > isobarbital > amylbarbital ~ amobarbital (see Table 3). This rank
order is almost completely opposite that observed in the resting nAChR
(see Table 2). Clearly, the binding site determinants in the resting
versus desensitized nAChRs are different. Yet, as was the case in the
resting state, the R(+)-enantiomers of both pentobarbital
and isobarbital are approximately 1.7-fold more potent than the
S(
)-enantiomers in inhibiting
[3H]TCP binding to the desensitized nAChR (Fig.
6B). Therefore the binding site in the resting and desensitized state
may have some structural features in common.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 6.
Barbiturate-induced inhibition of
[3H]TCP binding to desensitized nAChRs. nAChR-rich
membranes (0.2 µM) were equilibrated (1 h) with [3H]TCP
(~6.5 nM), CCh (250 µM), in the presence of increasing
concentrations (0.01-200 µM) of the barbiturate amobarbital ( ),
amylbarbital ( ), pentobarbital ( ), or isobarbital ( ) (A) and
the barbiturate enantiomers R(+)-pentobarbital ( ) and
S( )-pentobarbital ( ) (B). The nAChR membranes were
centrifuged and the radioactivity present in the pellets was measured
as described under Experimental Procedures. Nonspecific
binding was determined in the presence of 200 µM proadifen. Each plot
is the average of two different experiments. IC50 values
for each barbiturate was calculated by nonlinear least-squares fit for
a single binding site. Ki values for each
barbiturate were calculated using these IC50 values
according to eq. 2 and summarized in Table 3.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 3
Inhibition constant (Ki) for select barbiturates and
R(+)- or S( )-enantiomers determined by
inhibition of [3H]TCP binding to its high-affinity site on
the desensitized nAChR
The Ki values (averaged) were calculated using the
Cheng-Prusoff relationship (eq. 2) and the IC50 values obtained
from Fig. 6.
|
|
Given that the [14C]amobarbital equilibrium
binding results suggest that there are between 6 and 16 barbiturate
binding sites on the desensitized nAChR, we next sought to examine the
interaction of barbiturates with quinacrine, an NCA that binds to a
site distinct from the channel lumen (Arias, 1997
; reviewed in Arias,
1998
). The effect of pentobarbital on quinacrine binding was
determined. In this regard, the `apparent'
Kd values for quinacrine were determined in
the absence and in the presence of increasing concentrations of
pentobarbital. Examples of the results of a set of these titrations are
shown in Fig. 7A. This figure shows
typical quinacrine titrations performed in duplicate as the specific
(or proadifen-sensitive) fluorescence of quinacrine when binding to the
nAChR in the presence of CCh. The plots were best fit by nonlinear
regression for a single binding site. In the presence of pentobarbital,
the apparent Kd of quinacrine increased.
Thus, to determine the Ki of pentobarbital from the elicited displacement on nAChR-bound quinacrine, a Schild plot
was constructed (Fig. 7B). The Ki value,
obtained from the antilog of the x-intersect (when y = 0), was
found to be 135 µM. Because the slope from this plot is different
from one (0.36 ± 0.20), the calculated
Ki should be considered an "apparent
Ki". Because a slope value less than
unity indicates that the inhibitory process is not mediated by a
mutually exclusive action, an allosteric inhibitory mechanism instead
is plausible; therefore pentobarbital does not seem to bind to the
quinacrine binding locus on the desensitized nAChR. The location of
these additional barbiturate binding sites on the desensitized nAChR
remains to be established, with sites at the lipid-protein interface
being likely candidates.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 7.
Pentobarbital-induced inhibition of quinacrine
binding to its high-affinity site on the desensitized nAChR. A,
specific (proadifen-sensitive) fluorescence of quinacrine in the
absence ( ) or in the presence of 0.5 ( ), 1.0 ( ), or 1.5 mM
pentobarbital ( ). Quinacrine was directly titrated into
nAChR-containing membranes (0.3 µM) in the presence of CCh (1 mM),
and in the absence (control) or in the presence of pentobarbital.
Proadifen (200 µM) was used to determine nonspecific fluorescence.
Estimates of the apparent Kd values were
made by fitting plots of the specific changes in quinacrine
fluorescence versus the added ligand concentration to the equation for
a sigmoid curve. These plots are the average of duplicate experiments
and are examples of at least four separate determinations. B, Schild
plot for the effect of pentobarbital on the apparent
Kd value of quinacrine. The pentobarbital
apparent Ki value (135 µM) was obtained
from the antilog of the x-intersect according to eq. 3. The slope of
the plot is 0.36 ± 0.20.
|
|
 |
Discussion |
Barbiturate Interaction with the Resting nAChR.
The results of
equilibrium binding experiments demonstrate that amobarbital binds to a
single high-affinity (Kd = 3.7 µM) site
on the resting nAChR (Fig. 1). Based on the mutually exclusive nature
of barbiturate inhibition of [125I]TID
photoincorporation and [3H]tetracaine binding
(Fig. 4), this site is localized to the pore of the nAChR ion channel.
From studies examining the inhibition of
[125I]TID photoincorporation into the receptor
by different barbiturates, by formula isomers of amobarbital, and
stereoisomers of pentobarbital and isobarbital, it is evident that two
basic characteristics dominate barbiturate interaction with the resting
channel: (1) a minimal level of barbiturate hydrophobicity and (2)
steric hindrance. With respect to barbiturate hydrophobicity,
shortening the 5' chain of amylbarbital or amobarbital (Fig. 2) by
three carbons to produce barbital (5-ethyl, 5'-ethyl barbituric acid)
reduces the hydrophobic character of the barbiturate molecule and
results in a >500-fold reduction in potency for inhibition of
[125I]TID photoincorporation or
[14C]amobarbital binding (Dodson et al., 1990
;
de Armendi et al., 1993
) to the resting nAChR. On the other hand,
extending the length of the chain at the 5-position by an extra carbon
(CH2) converts pentobarbital to secobarbital,
resulting in an increase in hydrophobicity as measured by the
octanol/water partition coefficient (Dodson et al., 1990
) but with no
increase in potency for inhibition of [125I]TID
photoincorporation or [14C]amobarbital binding.
In other words, high-affinity binding to the nAChR channel site
requires that the barbiturate possess a minimum level of hydrophobic
character; going beyond that threshold level, however, increased
hydrophobicity does not seem to lead to increased binding affinity. The
dramatic difference in inhibition potencies between the formula isomers
of amobarbital (Figs. 2-4) clearly points out that steric constraints
play a significant role in barbiturate binding to the resting nAChR
channel. For example, by shifting the branch point on the 5' chain of
amobarbital [5-ethyl, 5'-(3-methylbutyl) barbituric acid] by one
carbon closer to the pyrimidine ring [i.e., isobarbital, 5-ethyl, 5'
(2-methylbutyl) barbituric acid] the result is a reduction of
>10-fold in the potency of inhibition of
[14C]amobarbital (Fig. 3) or
[3H]tetracaine binding (Fig. 4B) or
[125I]TID photoincorporation (Fig. 4A) into the
resting nAChR. The role of steric constraints in barbiturate binding to
the resting nAChR channel is further demonstrated by the ~2-fold
differences in potency of inhibition between the R(+)- and
S(
)-enantiomers of pentobarbital and isobarbital (Fig. 5).
Competition binding and photolabeling studies argue strongly that in
the resting nAChR, the high-affinity barbiturate binding site overlaps
that for tetracaine and TID (Figs. 4-5). The binding sites for TID
(White and Cohen, 1992
; Blanton et al., 2000
) and tetracaine (Gallagher
and Cohen, 1999
) in the resting nAChR channel have been extensively
characterized. Tetracaine and TID bind to overlapping sites in the
resting channel. For the smaller TID molecule, that site is located
between the highly conserved ring of leucine residues (M2-9, e.g.,
Leu-265) and the more extracellular ring of valine residues (M2-13,
e.g.,
Val-269). TID is similar in size to pentobarbital (or
amobarbital) and if we model pentobarbital complexed with the resting
nAChR channel (see Fig. 8), we see that
the barbiturate pyrimidine ring fits nicely in the TID binding site
[defined by M2-9 (Fig. 8, yellow) and M2-13 (Fig. 8, red)]. If the
barbiturate molecule is oriented such that the 5' chain extends
downward toward the intracellular end of the channel, we see that the
restriction in the lumen of the channel introduced by the leucine side
chains (M2-9) provides steric hindrance to barbiturate binding
depending on the conformation of the 5' chain (Fig. 8B). We propose
that the dramatic difference in inhibition potencies (i.e., binding
affinity) between amobarbital (or amylbarbital) and either
pentobarbital or isobarbital, result from the ability of the 5' chain
of amobarbital (or amylbarbital) to adopt a more extended conformation
compared with pentobarbital (or isobarbital). Therefore, the
amobarbital (or amylbarbital) molecule fits better in the narrow
crevice [i.e., the channel lumen (~3.5 Å; Unwin, 2000
)] created by
the ring of the leucine side chains (M2-9). Another possibility is
that the side chains of pentobarbital (or isobarbital) have less
rotational freedom than amobarbital (or amylbarbital). In either case,
the branching on the 5' chain of pentobarbital (or isobarbital) results
in a bulkier conformation that provides steric hindrance to the binding
of the barbiturate into the channel lumen.

View larger version (60K):
[in this window]
[in a new window]
|
Fig. 8.
Model of pentobarbital complexed with the resting
nAChR channel. Shown is a molecular dynamics model of the closed
(resting state) nAChR ion channel pore (Smith and Sansom, 1998 ). The
structure of pentobarbital was derived by molecular substitution (using
Sybyl; Tripos Inc., St. Louis, MO.) of the crystal structure of
-methylamobarbital (Smit and Kanters, 1974 ). Top, pentobarbital
(pyrimidine ring shown in orange) is placed at about the level of
residues at position 13 (M2-13, e.g., Val-269; shown in red). The
1-methylbutyl group of the 5' chain of pentobarbital (shown in green)
provides steric hindrance to pentobarbital binding as a result of the
restriction in the channel imposed by the side-chains of residues at
position 9 (M2-9, e.g., Leu-265; shown in yellow). For comparison,
the binding site for [125I]TID is defined by residues at
M2-9 and M2-13 (White and Cohen, 1992 ). Two M2 segments are not
displayed to better visualize pentobarbital within the pore. Bottom,
cross-sectional view of pentobarbital within the channel pore as viewed
from the cytoplasmic end.
|
|
Barbiturate Interaction with the Desensitized nAChR.
From
equilibrium binding studies we estimated that amobarbital binds with
very low affinity (Kd ~1 mM) to as many
as 6 to 16 binding sites on the desensitized nAChR. Despite such a
strong preference for interaction with the resting nAChR (~250-fold), we nonetheless wished to characterize the interaction of amobarbital and other barbiturates with the desensitized nAChR. As with the resting
nAChR, the ability of barbiturates to inhibit binding of the NCA
[3H]TCP to the receptor strongly suggests a
barbiturate binding site within the desensitized nAChR channel (Fig.
6). For example, amobarbital inhibits [3H]TCP
binding to the desensitized nAChR with a Ki
value of 1017 µM (Table 3; see also Cohen et al., 1986
), a result
that is in close agreement with our equilibrium binding results (Table
1). TCP is a close structural analog of PCP whose binding site in the
ion channel is believed to be located between the ring of leucine
residues (M2-9) and the more cytoplasmic ring of serine residues
(M2-6; Eaton et al., 2000
). The relative order of barbiturate potencies for inhibition of [3H]TCP binding to
the desensitized nAChR are nearly reversed from those for the resting
nAChR (compare Tables 2 and 3), suggesting that the structure-activity
relationships for binding to the desensitized nAChR are distinct from
those for binding to the resting nAChR channel. However, as with the
resting nAChR, the R(+)-enantiomers of pentobarbital and
isobarbital were roughly twice as potent in inhibiting
[3H]TCP binding than the
S(
)-enantiomers, suggesting at least some commonality
between the channel binding sites in each conformation. From the
equilibrium binding studies, it was estimated that there were as many
as 11 binding sites for amobarbital on the desensitized nAChR. Although
this value is an approximation, it suggests the presence of additional
binding sites on the desensitized nAChR distinct from the ion channel.
Barbiturates do not seem to interact with the quinacrine binding site
(Fig. 7), which is thought to be located at the nonannular lipid domain
(Arias, 1997
; reviewed in Arias, 1998
), and we are currently conducting
additional studies, including photoaffinity labeling experiments with
[14C]amobarbital, to identify these additional
sites of interaction. One possibility is that at least some of these
low-affinity barbiturate-binding sites are located at the lipid-protein
interface (annulus) of the desensitized nAChR.
Barbiturate Interaction with the Open Ion Channel.
In the
nAChR resting state, we found that amobarbital was approximately
20-fold more potent than pentobarbital in inhibiting either
[14C]amobarbital or
[3H]tetracaine binding, indicating a similar
difference in binding affinity to the resting channel. In contrast, the
reported inhibition constants for the open channel conformation
indicate a much smaller difference (1.4-fold) in potency between these
two barbiturates (Yost and Dodson, 1993
). Preliminary
electrophysiological experiments performed in ALL-11 cells expressing
T. californica nAChRs suggest that there is 4.9-fold
difference in channel-inhibition potency between amobarbital
(IC50 = 3.2 ± 0.2 µM) and pentobarbital
(IC50 = 15.6 ± 1.8 µM) (J. Dilger,
unpublished observations). Thus, the observed discrepancy may be caused
by the differences in the origin of the used nAChR. For instance, the
same barbiturates inhibit the mouse muscle nAChR expressed in
BC3-H1 cells with IC50
values of 22.8 ± 3.7 (amobarbital) and 22.6 ± 3.0 µM
(pentobarbital), respectively (J. Dilger, unpublished observations).
The affinity of amobarbital for the open channel of the T. californica nAChR is clearly similar to its affinity for
the resting state, but both affinities are higher than that for the
desensitized nAChR. On the contrary, pentobarbital exhibits a stronger
preference for the open channel state than for either the resting or
desensitized state (de Armendi et al., 1993
; Dilger et al., 1997
).
There is very little information pertaining to the location of the
barbiturate-binding site in the open channel. One study (Yost and
Dodson, 1993
), in which the triple mutation
Ser252Ala (on both
1 subunits) and
Thr265Ala (on the
1 subunit) decreased by
3.5-fold the dissociation rate constant of the local anesthetic QX-222
and by 3-fold the IC50 value for procaine, but
resulted in no affect on amobarbital induced inhibition, suggests that
the barbiturate binding site is not located between M2-6 and M2-10 in
the open channel (see also Yamakura et al., 2000
). Studies aimed at
localizing the barbiturate binding site within the nAChR open channel
as well as a more detailed characterization of the structure-activity
relationship for barbiturate binding, including stereochemistry, are
clearly warranted. Once the interaction of barbiturates with each
receptor conformation has been fully characterized perhaps then a
detailed mechanistic model of barbiturate inhibition of receptor
function can be developed.
Comparison with Other Ligand-Gated Ion Channel Members.
As
measured by the loss of righting reflex in mice, the
S(
)-enantiomer of pentobarbital is approximately 2-fold
more potent than the R(+)-enantiomer for inducing anesthesia
and the S(
)-enantiomer is approximately twice as potent in
potentiating chloride currents that flow through the
GABAAR (Tomlin et al., 1999
). Although these results provide evidence that the GABAAR is the
primary target for barbiturate-induced anesthesia, they (i.e., the
functional effects and the relative stereoselective potencies) also
point out the clear differences in the interaction of barbiturates with the structurally homologous members of this LGIC superfamily (reviewed in Krasowski and Harrison, 1999
). On the other hand, barbiturates exhibit similar affinities for the GABAAR and
nAChR, and although the stereoselectivity is reversed, the magnitudes
of the differences in stereoisomer potencies are also very similar
(Tonner and Miller, 1995
; Krasowski and Harrison, 1999
). Perhaps there
are common binding sites or at least common structural features for
barbiturate binding to different members of this LGIC superfamily. For
example, in this report, we demonstrate that amobarbital and other
barbiturates bind to a single high-affinity site localized within the
nAChR channel in the resting conformation. The pore-facing amino acid residues in this region of the channel (i.e., M2-9 through M2-13) are
well conserved in each of the different LGIC members, suggesting that a
common barbiturate-binding site might exist in each receptor, at least
in the resting state (Table 4).
It is striking that identical residues are present in the subunit A of
the mouse 5-HT3R and in the mouse or T. californica
1-,
1-, and
-subunits at positions M2-9 and
M2-13. Interestingly, pentobarbital inhibits
5-HT3R function (Barann et al., 1997
). However,
it is difficult to reconcile a barbiturate-binding site in the lumen of
the GABAAR (or glycine receptor) with
potentiation of agonist-induced currents. To try and resolve these
questions, we are presently pursuing studies aimed at directly
measuring [14C]amobarbital binding to
affinity-purified 5-HT3AR and
GABAAR.
We thank Drs. Tina Machu (Texas Tech University Health Sciences
Center, Lubbock, TX) and James Dilger (State University of New York at
Stony Brook, Stony Brook, NY) for their helpful comments and
suggestions. We thank Drs. Nick Franks and Robert Dickinson (Imperial
College of Science, Technology and Medicine, London) for providing us
with samples of purified R(+)- and
S(
)-pentobarbital to get started and for technical advice.
We also thank Dr. Jay Ponder (Washington University School of Medicine,
St. Louis, MO) for use of his computer workstation, molecular graphics
software, and invaluable assistance. Finally, we thank Drs. Mark Sansom and Graham Smith (University of Oxford, Oxford, England) for kindly providing the coordinates for their kinked
7 M2 molecular model.
This research was supported in part by National Institutes of
Health Grant R29-NS35786 (M.P.B.).
Dr. Hugo R. Arias. Department of
Pharmacology, School of Medicine, Texas Tech University Health Sciences
Center. 3601 4th Street, Lubbock, TX 79430. E-mail:
phrhra{at}ttuhsc.edu